Published on: October 17, 2017

Shanghai Runda Medical Technology Co., Ltd., Shanghai Runbo Investment Management Center (Limited Partnership), Wuhu Runjie Investment Management Center (Limited Partnership) and Ningbo Meishan Bonded Port Area Yongrui Equity Investment Partnership (Limited Partnership) jointly acquired 100% stocks of ReLIA Biotechnologies (Shenzhen) Inc. that were owned by Fantasy Art Limited, Ocean Hazel Limited, Allied Top Investment Holdings Limited, Blue Core Holdings Limited, WJR Biotech, Inc., Shenzhen Ruitao Enterprise Management Consulting (Limited Partnership), Shenzhen ReLIA Biotechnologies (Limited Partnership), Shenzhen Qisheng Consultation Management (Limited Partnership). The transaction amount is 1.179 billion Yuan.

Up to June 30, 2017, the total assets amount of ReLIA Biotech was RMB 222.7 million, total liabilities amount was RMB 87.77 million, and net assets amount was RMB 134.93 million. From January to June 2017, operating income was RMB 65.81 million, net profit was RMB 9.86 million. All the above data are audited.

As one of the major suppliers of POCT products in the domestic market, ReLIA Biotech has good market channel base, high-quality and mature product platforms. Through the acquisition of ReLIA Biotech, the company can gradually strengthen the promotion capability and channel construction of POCT products, enrich existing business structure and further enhance the company's comprehensive strength and profitability as well.